Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 18 October 2017

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

Novo Nordisk A/S    

Published: 23:22 CEST 18-10-2017 /GlobeNewswire /Source: Novo Nordisk A/S / : NOVO B /ISIN: DK0060534915

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

Bagsværd, Denmark, 18 October 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained. 

 

Based on the data included in the New Drug Application (NDA) for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults.

 

The recommendation for approval was based on a global development programme involving more than 8,000 adults with type 2 diabetes in the eight SUSTAIN phase 3a clinical trials, including a cardiovascular outcomes trial.

 

"Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. We look forward to working with the FDA as they complete their review of semaglutide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer.

 

The NDA for once-weekly semaglutide was submitted to the FDA in December 2016 under the US FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. Semaglutide is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

 

Conference call

On 19 October 2017 at 8.00 am CEST (2.00 am EDT), Novo Nordisk will host a conference call for investors. Investors will be able to listen in via a link on the investor section of novonordisk.com/investors.

 

About advisory committees

FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing data concerning the safety and efficacy of marketed drugs or new drug applications.

 

Further information

Media:

 

 

Katrine Sperling

+45 3079 6718

krsp@novonordisk.com

Ken Inchausti (US)

+1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 

Peter Hugreffe Ankersen

+45 3075 9085

phak@novonordisk.com

Hanna Ögren

+45 3079 8519

haoe@novonordisk.com

Anders Mikkelsen

+45 3079 4461

armk@novonordisk.com

Christina Kjær

+45 3079 3009

cnje@novonordisk.com

Kasper Veje (US)

+1 609 235 8567

kpvj@novonordisk.com


Company announcement No 80 / 2017 




PR171018_Semaglutide_adcom_UK



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Novo Nordisk A/S, Novo Allé, Bagsvaerd DK-2880, Denmark
If you would like to unsubscribe and stop receiving these e-mails click here.